(Q44946319)

7 December 2017

Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease (English)

1 reference

7 December 2017

0 references

Douglas Galasko

1

1 reference

7 December 2017

Paul R Kershaw

2

1 reference

7 December 2017

Lon Schneider

3

1 reference

7 December 2017

Young Zhu

4

1 reference

7 December 2017

Pierre N Tariot

5

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

Journal of the American Geriatrics Society

7 December 2017

1 reference

7 December 2017

52

1 reference

7 December 2017

7

1 reference

7 December 2017

1070-1076

1 reference

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

7 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2004.52303.X

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2004.52303.X

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2004.52303.X

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2004.52303.X

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2004.52303.X

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2004.52303.X

A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2004.52303.X

Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2004.52303.X

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2004.52303.X

Mental status as a predictor of daily function in progressive dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2004.52303.X

Measurement of functional activities in older adults in the community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2004.52303.X

Utility of Mini-Mental State Exam scores in predicting functional impairment among white and African American dementia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2004.52303.X

10.1111/J.1532-5415.2004.52303.X

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference